Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Rapid emergence of dolutegravir resistance on second-line dolutegravir-based ART

Naidoo K. et al, (2025), Southern African Journal of HIV Medicine, 26

Impact of increasing CD4 count threshold eligibility for antiretroviral therapy initiation on advanced HIV disease and tuberculosis prevalence and incidence in South Africa: an interrupted time series analysis.

Asare K. et al, (2025), BMJ Glob Health, 10

Risk of major adverse cardiovascular events with dolutegravir versus efavirenz-based antiretroviral therapy: emulated target trials using routine, de-identified data from South Africa

Dorward J. et al, (2025)

Uptake and 24-month outcomes of dolutegravir- versus lopinavir-based second-line antiretroviral therapy for people with HIV in South Africa: a retrospective cohort study and emulated target trial

Brown JA. et al, (2025)

Improving the quality of interpersonal care in HIV programmes

Tlhaku K. and DORWARD J., (2024), The Lancet HIV

High burden of Human Papillomavirus and pre-malignant cervical lesions among women starting HIV treatment in KwaZulu-Natal, South Africa

Naicker N. et al, (2024), Sexually Transmitted Infections

Favipiravir for COVID-19 in adults in the community in PRINCIPLE, an open-label, randomised, controlled, adaptive platform trial of short- and longer-term outcomes

Hobbs FR. et al, (2024), Journal of Infection, 89

Healthcare worker perspectives on adaptations to differentiated anti-retroviral therapy delivery during COVID-19 in South Africa: A qualitative inquiry

Tlhaku K. et al, (2024), PLOS Global Public Health, 4

Viremia and HIV Drug Resistance Among People Receiving Dolutegravir Versus Efavirenz-Based First-Line Antiretroviral Therapy

Dorward J. et al, (2024), Journal of Acquired Immune Deficiency Syndromes, 95, E8 - E11

Ivermectin for COVID-19 in adults in the community (PRINCIPLE): An open, randomised, controlled, adaptive platform trial of short- and longer-term outcomes

Hayward G. et al, (2024), Journal of Infection, 88

Urine tenofovir and dried blood spot tenofovir diphosphate concentrations and viraemia in people taking efavirenz and dolutegravir-based antiretroviral therapy

Dorward J. et al, (2024), AIDS, 38, 697 - 702

Early HIV viral suppression associated with subsequent 12‐month treatment success among people living with HIV in South Africa

Violette LR. et al, (2024), HIV Medicine

Randomized controlled trial of molnupiravir SARS-CoV-2 viral and antibody response in at-risk adult outpatients

Standing JF. et al, (2024), Nature communications, 15

Cost-utility analysis of molnupiravir plus usual care versus usual care alone as early treatment for community-based adults with COVID-19 and increased risk of adverse outcomes in the UK PANORAMIC trial.

Png ME. et al, (2024), Br J Gen Pract

Changes in the medical admissions and mortality amongst children in four South African hospitals following the COVID-19 pandemic: A five-year review.

Naidoo KL. et al, (2024), PLOS Glob Public Health, 4

Intimate Partner Violence and HIV Outcomes Among Women Living with HIV in Durban, South Africa

Ojeaburu SO. et al, (2024), AIDS and Behavior

Risk of major cardiovascular events with dolutegravir versus efavirenz-based antiretroviral therapy: retrospective cohort analyses using routine, de-identified data from South Africa

Dorward J. et al, (2024), JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 27, 20 - 20

Tenofovir-diphosphate concentrations and viral suppression following monthly point-of-care urine tenofovir testing among adults initiating antiretroviral therapy: primary outcome of the randomised controlled STREAM HIV trial

Garrett N. et al, (2024), JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 27, 105 - 106

Changes in the medical admissions and mortality amongst children in four South African hospitals following the COVID-19 pandemic : A five-year review

Loganathan NK. et al, (2023)

Clinical Outcomes After Viremia Among People Receiving Dolutegravir vs Efavirenz-Based First-line Antiretroviral Therapy in South Africa.

Asare K. et al, (2023), Open Forum Infect Dis, 10

Load More

1
2
3
4
5